Top

Published in:

01-07-2015 | Letter to the Editor

Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor

Authors: Joaquín Martinez-Lopez, Ana Jimenez, Jorge Sanchez-Calero, Dolores Monteagudo, María Urbanowicz, Irene Cañamares-Orbis, Susana Cortijo-Cascajares, Rosa Ayala

Published in: Annals of Hematology | Issue 7/2015

Excerpt

Dear Editor, …

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT et al (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98(12):1865–1871CrossRefPubMedCentralPubMed

Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F et al (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047–4053CrossRefPubMed

Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426–435CrossRefPubMed

Zauber NP, Vlad LD (1995) Myeloproliferative disorders in two New Jersey families. N J Med 92(8):530–532PubMed

Rochette J, Barnetson R, Kiger L, Kister J, Littlewood TJ, Webster R, Poyart C, Thein SL (1994) Association of a novel high oxygen affinity haemoglobin variant with delta beta thalassaemia. Br J Haematol 86(1):118–124CrossRefPubMed

Craig JE, Barnetson RA, Prior J, Raven JL, Thein SL (1994) Rapid detection of deletions causing delta beta thalassemia and hereditary persistence of fetal hemoglobin by enzymatic amplification. Blood 83(6):1673–1682PubMed

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113(20):4829–4833CrossRefPubMed

Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN (2013) Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 98(12):1872–1876CrossRefPubMedCentralPubMed

Lopes da Silva R, Silva M (2011) Coexistence of beta-thalassemia and polycythemia vera. Blood Cells Mol Dis 46(2):171–172CrossRefPubMed

Title: Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor
Authors: Joaquín Martinez-Lopez
Ana Jimenez
Jorge Sanchez-Calero
Dolores Monteagudo
María Urbanowicz
Irene Cañamares-Orbis
Susana Cortijo-Cascajares
Rosa Ayala
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 7/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-015-2352-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2015

Erythropoietin receptor mutation—a rush of blood to the head?

HFE hemochromatosis: influence of dietary iron intake on the iron overload of C282Y homozygous patients

Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman’s disease

MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation

HLA-DRB1 mismatch is associated with a decreased relapse in adult acute myeloid leukemia after single-unit myeloablative cord blood transplantation

Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page